Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ: ENVB )

0.3250 -0.0034 (-1.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
From Enveric Biosciences
Via Business Wire
New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Enveric Biosciences Announces Patent Granted for Drug Candidate
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Participate in BIO International Convention 2024
From Enveric Biosciences
Via Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the... 
Via Benzinga
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
Via Benzinga
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
From Enveric Biosciences
Via Business Wire
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
Exposures Glyphosate
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Via Benzinga
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
From Enveric Biosciences
Via Business Wire
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Nasdaq Down 100 Points; US Housing Starts Surge In February
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday?
Enveric Biosciences announces significant progress with non-binding term sheets signed with a biotech firm for cannabinoid-COX-2 conjugate compounds, targeting joint diseases. These agreements could... 
Via Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
From Enveric Biosciences
Via Business Wire
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.